Evidence map›Paper›PMID 41405450›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Reprogramming M2b Macrophages via GPX1 Activation by Selenium Nanoparticles Attenuates Lupus Nephritis.

Haoran Lv, Guanning Huang, Hongyu Li, Hanzhi Liang, Huajing Peng, Kefei Wu, Wenfang Chen, Dandan Zhang, Kexin Ma, Yufei Du and 7 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Haoran LvDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Guanning HuangState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Department of Chemistry, Jinan University, Guangzhou, China.
Hongyu LiDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Hanzhi LiangDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Huajing PengDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Kefei WuDepartment of Nephrology, Jieyang People's Hospital, Jieyang, China.
Wenfang ChenDepartment of Pathology, The First Affiliated Hospital, Sun Yatsen University, Guangzhou, 518000, China.
Dandan ZhangDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Kexin MaDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Yufei DuBasic and Translational Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Siweier LuoBasic and Translational Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Yi ZhouDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Haiping MaoDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Wei ChenDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Tianfeng ChenState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Department of Chemistry, Jinan University, Guangzhou, China.
Yiming ZhouBasic and Translational Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 518000, China.
Qinghua LiuDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 518000, China.ORCID https://orcid.org/0000-0002-6385-5482

Funding

China Postdoctoral Science Foundation 2023TQ0134China Postdoctoral Science Foundation 2024M751117China Postdoctoral Science Foundation GZC20230968Guangdong Basic and Applied Basic Research Foundation 2023A1515012477Guangdong Basic and Applied Basic Research Foundation 2025A1515010689National Natural Science Foundation of China 32171296National Natural Science Foundation of China 81970632National Natural Science Foundation of China 82225025National Natural Science Foundation of China 82470811
6 · The paper itself

Abstract

Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), is largely driven by dysregulated macrophage responses. However, the heterogeneity of macrophages hinders the development of targeted therapies for LN. Here, through single-cell analysis and clinical specimen validation, it is found that pro-inflammatory M2b macrophages are increased in the kidneys of patients with LN and are strongly associated with clinical indicators. To target and modulate M2b macrophages, mannose-functionalized selenium nanoparticles are engineered that can selectively suppress M2b polarization and activation by reducing reactive oxygen species (ROS), restoring mitochondrial function, and inducing selenoprotein glutathione peroxidase 1 (GPX1). In vivo, SeZM NPs accumulate in the kidneys of lupus mice and reduce M2b-derived pro-inflammatory cytokines, preserving renal structure and function. Together, these findings highlight pro-inflammatory M2b macrophages as pathogenic drivers of LN and demonstrate the translational potential of selenium-based nanotherapy.

Indexed as

Glutathione PeroxidaseLupus NephritisMacrophagesNanoparticlesSeleniumAnimalsDisease Models, AnimalFemaleGlutathione Peroxidase GPX1HumansMacrophage ActivationMiceReactive Oxygen SpeciesGlutathione PeroxidaseGlutathione Peroxidase GPX1GPX1 protein, humanReactive Oxygen SpeciesSeleniumlupus nephritisM2b macrophageselenium nanoparticlesselenoproteins

Identifiers

PMID41405450
PMCPMC12948211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.